This Article Full Text Full Text (PDF) All Versions of this Article: 107/21/2747    most recent 01.CIR.0000066912.58385.DEv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kalinowski, L. Articles by Malinski, T. Search for Related Content PubMed PubMed Citation Articles by Kalinowski, L. Articles by Malinski, T. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CARVEDILOL NITRIC OXIDE Related Collections Peripheral vascular disease Cardiovascular Pharmacology Receptor pharmacology Endothelium/vascular type/nitric oxide Hypertension - basic studies

(Circulation. 2003;107:2747.)
© 2003 American Heart Association, Inc.

Basic Science Reports

Third-Generation ß-Blockers Stimulate Nitric Oxide Release From Endothelial Cells Through ATP Efflux

A Novel Mechanism for Antihypertensive Action

Leszek Kalinowski, MD, PhD; Lawrence W. Dobrucki, PhD; Miroslawa Szczepanska-Konkel, PhD; Maciej Jankowski, MD, PhD; Ludmila Martyniec, MD; Stefan Angielski, MD, PhD; Tadeusz Malinski, PhD

From the Department of Chemistry and Biochemistry, Ohio University, Athens, Ohio (T.M., W.L.D.); and the Departments of Laboratory Medicine (L.K.) and Clinical Chemistry (M.S.K., M.J.), Medical University of Gdansk, and Laboratory of Cellular and Molecular Nephrology (L.K., M.J., M.S.K., L.M., S.A.), Medical Research Center of the Polish Academy of Science, Gdansk, Poland.

Correspondence to Tadeusz Malinski, Department of Chemistry and Biochemistry, Ohio University, Athens, OH 45701. E-mail malinski{at}ohiou.edu

Background— Nebivolol and carvedilol are third-generation ß-adrenoreceptor antagonists, which unlike classic ß-blockers, have additional endothelium-dependent vasodilating properties specifically related to microcirculation by a molecular mechanism that still remains unclear. We hypothesized that nebivolol and carvedilol stimulate NO release from microvascular endothelial cells by extracellular ATP, which is a well-established potent autocrine and paracrine signaling factor modulating a variety of cellular functions through the activation of P2-purinoceptors.

Methods and Results— Contraction and relaxation of renal glomerular vasculature were measured by determination of intracapillary volume with [³H]-inulin. Biologically active NO was measured with highly sensitive porphyrinic NO microsensors in a single glomerular endothelial cell (GEC). Extracellular ATP was measured by a luciferin-luciferase assay. Enzymatic degradation of extracellular ATP by apyrase and blockade of P2Y-purinoceptors by suramin or reactive blue 2 inhibited both ß-blocker–induced glomerular vasorelaxations and ß-blocker–stimulated NO release from GECs. Both ß-blocker–induced vasorelaxations were in the micromolar concentration range identical to that required for the ß-blocker stimulation of ATP and NO release from GECs. The maximum of NO release for nebivolol and carvedilol was very similar (188±14 and 226±17, respectively). Blockade of ATP release by a mechanosensitive ion channel blocker, Gd³⁺, inhibited the ß-blocker–dependent release of ATP and NO from GECs.

Conclusions— These results demonstrate for the first time that nebivolol and carvedilol induce relaxation of renal glomerular microvasculature through ATP efflux with consequent stimulation of P2Y-purinoceptor–mediated NO release from GECs.

Key Words: nitric oxide • endothelium • receptors, adrenergic, beta

This article has been cited by other articles:

				L. Moro, C. Pedone, S. Scarlata, V. Malafarina, F. Fimognari, and R. Antonelli-Incalzi Endothelial Dysfunction in Chronic Obstructive Pulmonary Disease Angiology, July 1, 2008; 59(3): 357 - 364. [Abstract] [PDF]

				L. M. Prisant Nebivolol: Pharmacologic Profile of an Ultraselective, Vasodilatory {beta}1-Blocker J. Clin. Pharmacol., February 1, 2008; 48(2): 225 - 239. [Abstract] [Full Text] [PDF]

				J. B. Buse, H. N. Ginsberg, G. L. Bakris, N. G. Clark, F. Costa, R. Eckel, V. Fonseca, H. C. Gerstein, S. Grundy, R. W. Nesto, et al. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association Circulation, January 2, 2007; 115(1): 114 - 126. [Abstract] [Full Text] [PDF]

				J. B. Buse, H. N. Ginsberg, G. L. Bakris, N. G. Clark, F. Costa, R. Eckel, V. Fonseca, H. C. Gerstein, S. Grundy, R. W. Nesto, et al. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association Diabetes Care, January 1, 2007; 30(1): 162 - 172. [Abstract] [Full Text] [PDF]

				M. Hirakawa, M. Oike, M. Watanabe, Y. Karashima, and Y. Ito Pivotal role of integrin {alpha}5{beta}1 in hypotonic stress-induced responses of human endothelium FASEB J, October 1, 2006; 20(12): 1992 - 1999. [Abstract] [Full Text] [PDF]

				J L Lattimore, I Wilcox, M Skilton, M Langenfeld, and D S Celermajer Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation Thorax, June 1, 2006; 61(6): 491 - 495. [Abstract] [Full Text] [PDF]

				R. P. Mason, L. Kalinowski, R. F. Jacob, A. M. Jacoby, and T. Malinski Nebivolol Reduces Nitroxidative Stress and Restores Nitric Oxide Bioavailability in Endothelium of Black Americans Circulation, December 13, 2005; 112(24): 3795 - 3801. [Abstract] [Full Text] [PDF]

				R. Bugiardini and C. N. Bairey Merz Angina With "Normal" Coronary Arteries: A Changing Philosophy JAMA, January 26, 2005; 293(4): 477 - 484. [Abstract] [Full Text] [PDF]

				J.-W. Chen, F.-Y. Lin, Y.-H. Chen, T.-C. Wu, Y.-L. Chen, and S.-J. Lin Carvedilol Inhibits Tumor Necrosis Factor-{alpha}-Induced Endothelial Transcription Factor Activation, Adhesion Molecule Expression, and Adhesiveness to Human Mononuclear Cells Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 2075 - 2081. [Abstract] [Full Text] [PDF]

				S. Wassmann, K. Wassmann, and G. Nickenig Modulation of Oxidant and Antioxidant Enzyme Expression and Function in Vascular Cells Hypertension, October 1, 2004; 44(4): 381 - 386. [Abstract] [Full Text] [PDF]

				Y. Liao, M. Asakura, S. Takashima, A. Ogai, Y. Asano, Y. Shintani, T. Minamino, H. Asanuma, S. Sanada, J. Kim, et al. Celiprolol, A Vasodilatory {beta}-Blocker, Inhibits Pressure Overload-Induced Cardiac Hypertrophy and Prevents the Transition to Heart Failure via Nitric Oxide-Dependent Mechanisms in Mice Circulation, August 10, 2004; 110(6): 692 - 699. [Abstract] [Full Text] [PDF]

				M. Hirakawa, M. Oike, Y. Karashima, and Y. Ito Sequential activation of RhoA and FAK/paxillin leads to ATP release and actin reorganization in human endothelium J. Physiol., July 15, 2004; 558(2): 479 - 488. [Abstract] [Full Text] [PDF]

				J. J. Olearczyk, M. L. Ellsworth, A. H. Stephenson, A. J. Lonigro, and R. S. Sprague Nitric Oxide Inhibits ATP Release from Erythrocytes J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1079 - 1084. [Abstract] [Full Text] [PDF]

				J. A. Joles and H. A. Koomans Causes and Consequences of Increased Sympathetic Activity in Renal Disease Hypertension, April 1, 2004; 43(4): 699 - 706. [Abstract] [Full Text] [PDF]